SI3348547T1 - Derivati benzimidazola kot zaviralci NAV 1.7 (natrijevi kanalčki, napetostno odvisni, tip IX, podenota alfa (SCN9A)) za zdravljenje bolečine, disurije in multiple skleroze - Google Patents
Derivati benzimidazola kot zaviralci NAV 1.7 (natrijevi kanalčki, napetostno odvisni, tip IX, podenota alfa (SCN9A)) za zdravljenje bolečine, disurije in multiple sklerozeInfo
- Publication number
- SI3348547T1 SI3348547T1 SI201630917T SI201630917T SI3348547T1 SI 3348547 T1 SI3348547 T1 SI 3348547T1 SI 201630917 T SI201630917 T SI 201630917T SI 201630917 T SI201630917 T SI 201630917T SI 3348547 T1 SI3348547 T1 SI 3348547T1
- Authority
- SI
- Slovenia
- Prior art keywords
- scn9a
- dysuria
- nav
- gated
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015179663 | 2015-09-11 | ||
| PCT/JP2016/076645 WO2017043636A1 (ja) | 2015-09-11 | 2016-09-09 | 新規ベンズイミダゾール化合物およびその医薬用途 |
| EP16844497.4A EP3348547B1 (en) | 2015-09-11 | 2016-09-09 | Benzimidazole derivatives as nav 1.7 (sodium channel, voltage-gated, type ix, alpha subunit (scn9a)) inhibitors for treating pain, dysuria and multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3348547T1 true SI3348547T1 (sl) | 2020-10-30 |
Family
ID=58239905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201630917T SI3348547T1 (sl) | 2015-09-11 | 2016-09-09 | Derivati benzimidazola kot zaviralci NAV 1.7 (natrijevi kanalčki, napetostno odvisni, tip IX, podenota alfa (SCN9A)) za zdravljenje bolečine, disurije in multiple skleroze |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10407395B2 (sl) |
| EP (1) | EP3348547B1 (sl) |
| JP (1) | JP6768674B2 (sl) |
| KR (1) | KR102654710B1 (sl) |
| CN (1) | CN107922350B (sl) |
| AU (1) | AU2016319597B2 (sl) |
| CA (1) | CA2989992A1 (sl) |
| CY (1) | CY1123482T1 (sl) |
| DK (1) | DK3348547T3 (sl) |
| ES (1) | ES2818529T3 (sl) |
| HK (1) | HK1251225A1 (sl) |
| HU (1) | HUE052395T2 (sl) |
| LT (1) | LT3348547T (sl) |
| PL (1) | PL3348547T3 (sl) |
| PT (1) | PT3348547T (sl) |
| SI (1) | SI3348547T1 (sl) |
| TW (1) | TWI710554B (sl) |
| WO (1) | WO2017043636A1 (sl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2818529T3 (es) * | 2015-09-11 | 2021-04-13 | Sumitomo Dainippon Pharma Co Ltd | Derivados de bencimidazol como inhibidores Nav 1.7 (subunidad alfa del canal de sodio, dependiente del voltaje, tipo IX (SCN9A)) para tratar el dolor, la disuria y la esclerosis múltiple |
| WO2018168899A1 (ja) * | 2017-03-15 | 2018-09-20 | 大日本住友製薬株式会社 | ベンズイミダゾール誘導体の製造方法 |
| JP7090069B2 (ja) * | 2017-03-15 | 2022-06-23 | 住友ファーマ株式会社 | 重水素化ベンズイミダゾール化合物およびその医薬用途 |
| JP7165501B2 (ja) * | 2017-03-15 | 2022-11-04 | 住友ファーマ株式会社 | 新規ベンズイミダゾール化合物からなる医薬 |
| KR102183676B1 (ko) | 2018-04-17 | 2020-11-27 | 주식회사 엘지화학 | 타원 편광판 및 유기발광장치 |
| CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1501833B1 (en) | 2002-04-26 | 2005-11-02 | Pfizer Products Inc. | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| NZ547109A (en) * | 2003-10-28 | 2010-03-26 | Vertex Pharma | Benzimidazoles useful as modulators of ion channels |
| US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| EP2582666B1 (en) | 2010-06-16 | 2014-08-13 | Purdue Pharma L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
| KR20130130729A (ko) | 2010-10-28 | 2013-12-02 | 니뽄 신야쿠 가부시키가이샤 | 피리딘 유도체 및 의약 |
| EP2681200A4 (en) * | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL |
| WO2012172043A1 (en) * | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| CA2861439C (en) | 2012-02-03 | 2016-07-12 | Pfizer Inc. | Benzimidazole and imidazopyridine derivatives as sodium channel modulators |
| EP2905279A4 (en) | 2012-10-02 | 2016-04-20 | Sumitomo Dainippon Pharma Co Ltd | imidazole |
| AU2014244183A1 (en) * | 2013-03-13 | 2015-08-13 | Abbvie Inc. | Pyridine CDK9 kinase inhibitors |
| JP2016169161A (ja) * | 2013-07-19 | 2016-09-23 | 大日本住友製薬株式会社 | 新規イミダゾピリジン化合物 |
| US9828348B2 (en) * | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| MA40957A (fr) * | 2014-10-09 | 2017-09-19 | Biomarin Pharm Inc | Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies |
| JP2018052817A (ja) * | 2015-01-21 | 2018-04-05 | 大日本住友製薬株式会社 | 新規ベンズイミダゾール誘導体およびその医薬用途 |
| MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| US9814698B2 (en) | 2015-04-21 | 2017-11-14 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| ES2818529T3 (es) * | 2015-09-11 | 2021-04-13 | Sumitomo Dainippon Pharma Co Ltd | Derivados de bencimidazol como inhibidores Nav 1.7 (subunidad alfa del canal de sodio, dependiente del voltaje, tipo IX (SCN9A)) para tratar el dolor, la disuria y la esclerosis múltiple |
-
2016
- 2016-09-09 ES ES16844497T patent/ES2818529T3/es active Active
- 2016-09-09 CA CA2989992A patent/CA2989992A1/en active Pending
- 2016-09-09 KR KR1020187007320A patent/KR102654710B1/ko active IP Right Grant
- 2016-09-09 CN CN201680052438.1A patent/CN107922350B/zh active Active
- 2016-09-09 SI SI201630917T patent/SI3348547T1/sl unknown
- 2016-09-09 AU AU2016319597A patent/AU2016319597B2/en active Active
- 2016-09-09 PT PT168444974T patent/PT3348547T/pt unknown
- 2016-09-09 PL PL16844497T patent/PL3348547T3/pl unknown
- 2016-09-09 HU HUE16844497A patent/HUE052395T2/hu unknown
- 2016-09-09 EP EP16844497.4A patent/EP3348547B1/en active Active
- 2016-09-09 TW TW105129360A patent/TWI710554B/zh active
- 2016-09-09 DK DK16844497.4T patent/DK3348547T3/da active
- 2016-09-09 LT LTEP16844497.4T patent/LT3348547T/lt unknown
- 2016-09-09 US US15/323,185 patent/US10407395B2/en active Active
- 2016-09-09 WO PCT/JP2016/076645 patent/WO2017043636A1/ja active Application Filing
- 2016-09-09 JP JP2017538545A patent/JP6768674B2/ja active Active
- 2016-12-30 US US15/395,338 patent/US9688670B2/en active Active
-
2018
- 2018-08-17 HK HK18110573.4A patent/HK1251225A1/zh unknown
-
2020
- 2020-10-14 CY CY20201100973T patent/CY1123482T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017043636A1 (ja) | 2017-03-16 |
| KR20180044317A (ko) | 2018-05-02 |
| ES2818529T3 (es) | 2021-04-13 |
| RU2018105683A (ru) | 2019-10-14 |
| KR102654710B1 (ko) | 2024-04-03 |
| CY1123482T1 (el) | 2022-03-24 |
| TW201713629A (zh) | 2017-04-16 |
| US20170107211A1 (en) | 2017-04-20 |
| CN107922350A (zh) | 2018-04-17 |
| US9688670B2 (en) | 2017-06-27 |
| CN107922350B (zh) | 2022-04-19 |
| JP6768674B2 (ja) | 2020-10-14 |
| EP3348547A4 (en) | 2019-03-20 |
| PT3348547T (pt) | 2020-10-12 |
| PL3348547T3 (pl) | 2020-12-14 |
| RU2018105683A3 (sl) | 2019-12-26 |
| HUE052395T2 (hu) | 2021-04-28 |
| JPWO2017043636A1 (ja) | 2018-06-28 |
| US20180170881A1 (en) | 2018-06-21 |
| HK1251225A1 (zh) | 2019-01-25 |
| LT3348547T (lt) | 2020-11-10 |
| EP3348547A1 (en) | 2018-07-18 |
| EP3348547B1 (en) | 2020-07-22 |
| CA2989992A1 (en) | 2017-03-16 |
| AU2016319597A1 (en) | 2018-02-01 |
| US10407395B2 (en) | 2019-09-10 |
| TWI710554B (zh) | 2020-11-21 |
| AU2016319597B2 (en) | 2020-12-24 |
| DK3348547T3 (da) | 2020-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE052395T2 (hu) | Benzimidazol-származékok mint NAV 1.7 (nátriumcsatorna, feszültségkapuzott, IX típusú, alfa alegység (SCN9A) inhibitorok fájdalom, diszúria és szklerózis multiplex kezelésére | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| SI3805233T1 (sl) | (r)in (s) enantiomera n-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo(4,5-b)piridin-6-il) -2-(2-metilpiridin-4-il)oksazol-karboksamid kot inhibitorji irak4 za zdravljenje raka | |
| GB2541571A (en) | Pharmaceutical compositions | |
| ZA201904387B (en) | Compositions and methods for treating, ameliorating and preventing h. pylori | |
| WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
| SG11202008132UA (en) | Composition, method and use | |
| IL271728A (en) | Materials, uses and treatment methods | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| GB201504607D0 (en) | Methods,tools and systems for the assessment,preventation,management and treatment selection for type 2 diabetes | |
| EP3646855C0 (en) | COMPOSITION FOR SOLID PREPARATION FOR ORAL USE COMPRISING A PROTON PUMP INHIBITOR, SOLID PREPARATION FOR ORAL USE COMPRISING SAME, AND METHOD FOR PREPARING SAME | |
| IL286646A (en) | Preparations, devices and methods for the treatment of Fabry disease | |
| GB201705124D0 (en) | Composition, method and use | |
| GB2564511B (en) | Composition, method and use | |
| GB201805016D0 (en) | Composition, method and use | |
| IL258610B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof for use in the treatment of cancer | |
| GB2539742B (en) | Therapeutic treatment methods, and apparatus for use therein | |
| GB2543709A (en) | Pharmaceutical agent | |
| GB2579240B (en) | New processes, compositions and medical uses | |
| GB201907832D0 (en) | Medical uses, methods and uses | |
| ZA201704287B (en) | 3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of cns disorders | |
| GB2553684B (en) | Ethynylxanthines, preparation and use for cancer treatment |